Vor Biopharma shares jump 10.65% intraday on positive telitacicept Phase 3 data and JPMorgan upgrade.

Vor Biopharma surged 10.65% intraday following the release of positive Phase 3 data for telitacicept in IgA nephropathy and upbeat coverage from JPMorgan. The Phase 3 results, which demonstrated the drug’s efficacy, combined with the analyst’s favorable outlook on its long-term commercial potential, immediately boosted investor sentiment. This aligns with the stock’s recent 28.23% one-day return and 25.97% seven-day gain, as the news reset expectations for the biotech’s pipeline. While the stock remains down sharply over one and three years, the DCF valuation model suggests shares are undervalued at $10.72, with a fair value of $15.08, further supporting the bullish momentum. The intraday rally reflects market confidence in the drug’s regulatory and commercial prospects despite broader long-term risks.